Australia's Pharmaxis set for best day in two weeks on clinical phase funding

Syntara

01/09/2022 04:49

** Shares of Pharmaxis  PXS.AX  jump as much as 7.9% to
A$0.082, set for their best day in two weeks, if gains hold 
    ** The biopharma co says it will receive about A$5 mln from
charity house Parkinson's UK to fund a second phase clinical
study to investigate its drug PXS‐4728, to cure Parkinson's and
other diseases  urn:newsml:reuters.com:*:nFWN3071VL
    ** Shares hit highest level since Aug 16 
    ** Pharmaxis stock down 36.7% this year, as of last close

 (Reporting by Archishma Iyer)
 ((Archishma.Iyer@thomsonreuters.com;))